Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. 113-24-6
2. Sodium 2-oxopropanoate
3. Pyruvic Acid Sodium Salt
4. Pyruvate Sodium
5. Pyruvic Acid, Sodium Salt
6. Propanoic Acid, 2-oxo-, Sodium Salt
7. Natrum Pyruvicum
8. 2-oxopropanoic Acid Sodium Salt
9. Alpha-ketopropionic Acid Sodium Salt
10. 113-24-6 (sodium)
11. Mfcd00002586
12. Pod38aif08
13. 2-ketopropionic Acid Sodium Salt
14. Chebi:50144
15. Natriumpyruvat
16. Propanoic Acid, 2-oxo-, Sodium Salt (1:1)
17. Sodium Alpha-ketopropionate
18. Sodiumpyruvate
19. Chembl181886
20. Unii-pod38aif08
21. Sodium-pyruvate
22. Guna-flam
23. Guna-hypertension
24. Einecs 204-024-4
25. Sodium;2-oxopropanoate
26. Sodium 2-oxo-propionate
27. Dsstox_cid_20614
28. Dsstox_rid_79512
29. Dsstox_gsid_40614
30. Schembl18226
31. Sodium Pyruvate [inci]
32. 113-24-6 (solid)
33. Sodium 2-oxidanylidenepropanoate
34. 2-oxopropionic Acid Sodium Salt
35. Natrum Pyruvicum [hpus]
36. A-ketopropionic Acid Sodium Salt
37. Dtxsid6040614
38. Sodium Pyruvate [mart.]
39. Sodium Pyruvate [who-dd]
40. Amy25534
41. Bcp30592
42. Sodium Pyruvate, Cell Culture Grade
43. Tox21_301486
44. Akos015895160
45. Cs-w016629
46. Hy-w015913
47. Pyruvic Acid, Sodium Salt (7ci,8ci)
48. Ncgc00255495-01
49. Cas-113-24-6
50. Sodium Pyruvate Solution 100 Mm (100x)
51. Ft-0631651
52. Ft-0674253
53. P0582
54. Propanoic Acid, 2-oxo-, Sodium Salt (9ci)
55. D77796
56. Pyruvic Acid Sodium Salt Rgt Grd 100g
57. Pyruvic Acid Sodium Salt;sodium 2-oxopropanoate
58. S-6005
59. (r)octahydro-1h-indole-2-carboxylicacid
60. A803033
61. J-002928
62. Q3905673
| Molecular Weight | 110.04 g/mol |
|---|---|
| Molecular Formula | C3H3NaO3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 109.99798824 g/mol |
| Monoisotopic Mass | 109.99798824 g/mol |
| Topological Polar Surface Area | 57.2 Ų |
| Heavy Atom Count | 7 |
| Formal Charge | 0 |
| Complexity | 88.2 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35931
Submission : 2021-07-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12982
Submission : 1998-05-04
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4546
Submission : 1982-05-18
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Lead Product(s): Sodium Pyruvate,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: General University Hospital, Prague
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2023

Lead Product(s) : Sodium Pyruvate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of N115 on Coughing in IPF Patients
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels and synthesis of nasal nitric oxide. N115 Non-Steroidal Nasal Spray could be used as safe, effective treatment to help alleviate the symptoms associated with COVID-19 infections.
Lead Product(s): Sodium Pyruvate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Pyruvate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels and synthesis of nasal nitric oxide. N115 Non-Steroidal Nasal Spray could be used as safe, effective treatment to help alleviate the symptoms associated with ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2021

Details:
Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Post-Acute COVID-19 Syndrome.
Lead Product(s): Sodium Pyruvate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2021

Lead Product(s) : Sodium Pyruvate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Post-Acute COVID-19 Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2021

Details:
Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Lead Product(s): Sodium Pyruvate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2021

Lead Product(s) : Sodium Pyruvate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
EmphyCorp's globally patented formula has Completed All Three Phases of Clinical Trials required by the FDA to prove safety and efficacy in treating the Pulmonary Fibrosis.
Lead Product(s): Sodium Pyruvate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Pyruvate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EmphyCorp N115 Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide
Details : EmphyCorp's globally patented formula has Completed All Three Phases of Clinical Trials required by the FDA to prove safety and efficacy in treating the Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Dosage Form : Injectable / Parenteral
Grade : Biopharma Grade
Brand Name : Citric Acid Monohydrate
Application : Thickeners and Stabilizers
Excipient Details : Used as a pH regulator and preservative in many Biological formulations and cell culture media. Also it can be used as a chelating agent.
Pharmacopoeia Ref : On Request
Technical Specs : Low bacteria endotoxins, low bioburden (TAMC/TYMC). Customised packaging (from grs to kilograms)
Ingredient(s) : Citric Acid Excipient
Dosage Form : Injectable / Parenteral
Grade : Biopharma Grade
Application : Thickeners and Stabilizers
Excipient Details : Used as carbon source in cell cultures in upstream, cryoprotectant and stabilizer in lyophilized formulations.
Pharmacopoeia Ref : On Request
Technical Specs : Low bacteria endotoxins, low bioburden (TAMC/TYMC). Customised packaging (from grs to kilograms)
Ingredient(s) : Saccharose Excipient
Dosage Form : Injectable / Parenteral
Grade : Biopharma Grade
Application : Parenteral
Excipient Details : Used as an osmolarity agent in culture media, tonicity adjuster in ophthalmics and parenterals solutions.
Pharmacopoeia Ref : On Request
Technical Specs : Low bacteria endotoxins, low bioburden (TAMC/TYMC). Customised packaging (from grs to kilograms)
Ingredient(s) : Sodium Chloride Excipient
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
ANALYTICAL
ABOUT THIS PAGE
53
PharmaCompass offers a list of Sodium Pyruvate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sodium Pyruvate manufacturer or Sodium Pyruvate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Pyruvate manufacturer or Sodium Pyruvate supplier.
PharmaCompass also assists you with knowing the Sodium Pyruvate API Price utilized in the formulation of products. Sodium Pyruvate API Price is not always fixed or binding as the Sodium Pyruvate Price is obtained through a variety of data sources. The Sodium Pyruvate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sodium Pyruvate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sodium Pyruvate, including repackagers and relabelers. The FDA regulates Sodium Pyruvate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sodium Pyruvate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sodium Pyruvate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sodium Pyruvate supplier is an individual or a company that provides Sodium Pyruvate active pharmaceutical ingredient (API) or Sodium Pyruvate finished formulations upon request. The Sodium Pyruvate suppliers may include Sodium Pyruvate API manufacturers, exporters, distributors and traders.
click here to find a list of Sodium Pyruvate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sodium Pyruvate DMF (Drug Master File) is a document detailing the whole manufacturing process of Sodium Pyruvate active pharmaceutical ingredient (API) in detail. Different forms of Sodium Pyruvate DMFs exist exist since differing nations have different regulations, such as Sodium Pyruvate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sodium Pyruvate DMF submitted to regulatory agencies in the US is known as a USDMF. Sodium Pyruvate USDMF includes data on Sodium Pyruvate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sodium Pyruvate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sodium Pyruvate suppliers with USDMF on PharmaCompass.
Sodium Pyruvate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sodium Pyruvate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sodium Pyruvate GMP manufacturer or Sodium Pyruvate GMP API supplier for your needs.
A Sodium Pyruvate CoA (Certificate of Analysis) is a formal document that attests to Sodium Pyruvate's compliance with Sodium Pyruvate specifications and serves as a tool for batch-level quality control.
Sodium Pyruvate CoA mostly includes findings from lab analyses of a specific batch. For each Sodium Pyruvate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sodium Pyruvate may be tested according to a variety of international standards, such as European Pharmacopoeia (Sodium Pyruvate EP), Sodium Pyruvate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sodium Pyruvate USP).